BIVI - CIK 0001580149
The table below shows BIOVIE INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $9.27M | $23.10M | $33.30M | $17.26M | $2.54M | $1.15M |
| SG&A | $8.57M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $8.85M |
| $11.55M |
| $9.77M |
| $4.64M |
| $1.31M |
| Operating income | -$18.07M | -$32.18M | -$45.08M | -$27.25M | -$138.05M | -$2.69M |
| Income tax | - | - | - | - | - | - |
| Net income | -$17.54M | -$32.12M | -$50.26M | -$26.08M | -$130.25M | -$16.68M |
| EPS (diluted) | -$12.12 | -$73.05 | -$15.47 | -$1.06 | -$14.82 | -$6.85 |